Roche: marketing authorisation for Tecentriq.
(CercleFinance.com) - There is some good news for Roche, which has announced that it has obtained a marketing authorisation for Tecentric (atezolizumab) from Swissmedic, for the treatment of metastatic non-small cell lung cancer (NSCLC).
The Swiss pharmaceutical giant specified that this treatment is the first and only anti-PD-L1 immuno-therapeutic drug approved by Swissmedic in this indication.
Interviewed by the Sonntagszeitung, Severin Schwan, managing director of Roche, was also reassuring about Perjeta, which could be subject to a class action in the US. A law firm accuses the group of being too confident about the drug used in the treatment early-stage breast cancer.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The Swiss pharmaceutical giant specified that this treatment is the first and only anti-PD-L1 immuno-therapeutic drug approved by Swissmedic in this indication.
Interviewed by the Sonntagszeitung, Severin Schwan, managing director of Roche, was also reassuring about Perjeta, which could be subject to a class action in the US. A law firm accuses the group of being too confident about the drug used in the treatment early-stage breast cancer.
Copyright (c) 2017 CercleFinance.com. All rights reserved.